An interventional study of Linear ablation and PVI alone in Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to PVI outperforms PVI alone using PFA in maintaining sinus rhythm for PerAF. Enrolled subjects will be randomized by the ratio of 1:1 into PVI and linear ablation arm or PVI alone arm. Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device and EIVOM could be performed additionally before or after PFA at the operator's discretion, it is recommended to perform EIVOM first. Subjects randomized to the PVI alone arm will undergo PVI only. If atrial fibrillation (AF) cannot be terminated during ablation, cardioversion will be performed. After ablation, all the subjects will be followed at discharge, 1 month and then at 3-month intervals up to 12 months.
Study subjects are required to meet all the following inclusion criteria:
Subjects have symptomatic, drug-resistant, persistent AF, defined as:
Exclusion Criteria:
Any of the following events within 90 days of the Consent Date:
Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device, and EIVOM could be performed additionally before or after PFA at the operator's discretion.
Procedure: Linear ablation · Procedure: PVI alone
Subjects randomized to the PVI alone arm will undergo PVI only with the study device.
Procedure: PVI alone
Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.
Undergo PVI with the study device
Primary Effectiveness Endpoint with Treatment Success.
Number of Participants free from Arrhythmia, Re-ablation, Cardioversion, and AAD use.
Time frame: Completion of treatment 360 days compared with the baseline
Primary Safety Endpoint with Safety events related to AF catheter ablation.
Number of Participants with following device or procedure-related serious Composite Adverse Events (CAEs).
Time frame: Completion of treatment 360 days compared with the baseline
Secondary Effectiveness Endpoint with Chronic Success.
Number of Participants with Chronic Success, Freedom from any documented AF, AFL or AT episode lasting ≥10s via 12-lead ECG or ≥30s via Holter (or other continuous rhythm monitoring device) on/off AADs after the blanking period to Day 360.
Time frame: Completion of treatment 360 days compared with the baseline.
Secondary Safety Endpoint with Non-SAE.
Number of Participants with Non-Serious Composite Adverse Event
Time frame: Completion of treatment 360 days compared with the baseline
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation